LU91504I2 - Ranolazine ou un de ses sels ou solvates - Google Patents

Ranolazine ou un de ses sels ou solvates

Info

Publication number
LU91504I2
LU91504I2 LU91504C LU91504C LU91504I2 LU 91504 I2 LU91504 I2 LU 91504I2 LU 91504 C LU91504 C LU 91504C LU 91504 C LU91504 C LU 91504C LU 91504 I2 LU91504 I2 LU 91504I2
Authority
LU
Luxembourg
Prior art keywords
ranolazine
solvate
salt
Prior art date
Application number
LU91504C
Other languages
English (en)
French (fr)
Other versions
LU91504I9 (en:Method
Original Assignee
Roche Palo Alto Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26796494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91504(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Palo Alto Llc filed Critical Roche Palo Alto Llc
Publication of LU91504I2 publication Critical patent/LU91504I2/fr
Publication of LU91504I9 publication Critical patent/LU91504I9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
LU91504C 1998-09-10 2008-12-03 Ranolazine ou un de ses sels ou solvates LU91504I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9980498P 1998-09-10 1998-09-10
US09/321,522 US6303607B1 (en) 1998-09-10 1999-05-27 Method for administering a sustained release ranolanolazine formulation
PCT/US1999/020967 WO2000013686A2 (en) 1998-09-10 1999-09-09 Sustained release ranolazine formulations

Publications (2)

Publication Number Publication Date
LU91504I2 true LU91504I2 (fr) 2009-02-03
LU91504I9 LU91504I9 (en:Method) 2019-01-02

Family

ID=26796494

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91504C LU91504I2 (fr) 1998-09-10 2008-12-03 Ranolazine ou un de ses sels ou solvates

Country Status (33)

Country Link
US (14) US6303607B1 (en:Method)
EP (3) EP1527779A1 (en:Method)
JP (2) JP3745621B2 (en:Method)
KR (1) KR100475759B1 (en:Method)
CN (2) CN1211086C (en:Method)
AR (3) AR022085A1 (en:Method)
AT (2) ATE217794T1 (en:Method)
AU (4) AU744071B2 (en:Method)
BR (2) BR9913553A (en:Method)
CA (2) CA2342390C (en:Method)
CY (1) CY2008020I1 (en:Method)
CZ (2) CZ301375B6 (en:Method)
DE (3) DE69901570T2 (en:Method)
DK (2) DK1096937T3 (en:Method)
ES (2) ES2234302T3 (en:Method)
FR (1) FR09C0001I2 (en:Method)
GE (1) GEP20053420B (en:Method)
HK (1) HK1044284B (en:Method)
HU (2) HUP0104088A3 (en:Method)
IL (6) IL141892A0 (en:Method)
LU (1) LU91504I2 (en:Method)
MX (2) MXPA01002599A (en:Method)
NL (1) NL300371I2 (en:Method)
NO (4) NO319434B1 (en:Method)
NZ (2) NZ510386A (en:Method)
PL (3) PL202207B1 (en:Method)
PT (2) PT1109558E (en:Method)
RU (2) RU2214233C2 (en:Method)
SI (2) SI1109558T1 (en:Method)
TR (2) TR200101261T2 (en:Method)
TW (1) TWI241911B (en:Method)
UA (2) UA67793C2 (en:Method)
WO (2) WO2000013686A2 (en:Method)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
WO2001060348A2 (en) 2000-02-18 2001-08-23 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
WO2002007716A2 (en) * 2000-07-21 2002-01-31 Cv Therapeutics, Inc. Method for treating angina
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
AU2003246791A1 (en) * 2002-04-09 2003-10-20 Flamel Technologies Oral suspension of amoxicillin capsules
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
NZ536678A (en) 2002-05-21 2007-01-26 Cv Therapeutics Inc Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
UA90875C2 (ru) * 2005-01-06 2010-06-10 СиВи СЕРАПЬЮТИКС, ИНК. Лекарственные формы пролонгированного действия, которые содержат ранолазин
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
WO2007016350A2 (en) * 2005-07-28 2007-02-08 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
WO2007108362A1 (ja) * 2006-03-17 2007-09-27 Konica Minolta Holdings, Inc. 有機エレクトロルミネッセンス素子、表示装置および照明装置
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
JP2010518181A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 心血管疾患の処置のためのラノラジンの使用
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008101012A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20080248112A1 (en) * 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
ES2395241T3 (es) * 2007-03-07 2013-02-11 Concert Pharmaceuticals Inc. Derivados deuterados de piperazina como compuestos antianginosos
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
CN101896181A (zh) * 2007-05-31 2010-11-24 吉利德帕洛阿尔托股份有限公司 用于升高的脑钠肽的雷诺嗪
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
CA2690379A1 (en) * 2007-06-13 2008-12-24 Auspex Pharmaceuticals, Inc. Substituted piperazines
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
WO2009100380A1 (en) * 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of ranolazine for treating pain
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
WO2010137040A2 (en) 2009-05-28 2010-12-02 Lupin Limited Novel pharmaceutical compositions of ranolazine
EP2480234B1 (en) * 2009-09-25 2020-02-26 Lupin Limited Sustained release composition of ranolazine
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
ES2414384T3 (es) 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
NO3175985T3 (en:Method) 2011-07-01 2018-04-28
HK1200114A1 (en) 2011-09-21 2015-07-31 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
US20160305924A1 (en) * 2013-04-26 2016-10-20 Laguna Pharmaceuticals , Inc. Methods for calibrating the administration of vanoxerine for terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rhythm in mammals
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10898444B2 (en) 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)
CN110898024A (zh) * 2019-12-17 2020-03-24 卓和药业集团有限公司 一种治疗心绞痛的药物组合物及制备方法
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
WO2023130028A1 (en) 2021-12-31 2023-07-06 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
NZ247044A (en) * 1989-06-23 1997-04-24 Syntex Usa Inc Substituted For Use of ranolazine and related piperazine derivatives to treat tissue affected by muscle and neuronal damage, including transplant tissue
US5527545A (en) 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH08259446A (ja) * 1995-01-24 1996-10-08 Mitsui Toatsu Chem Inc 持効性医薬製剤
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation

Also Published As

Publication number Publication date
US20030166659A1 (en) 2003-09-04
US6620814B2 (en) 2003-09-16
US6503911B2 (en) 2003-01-07
US20040097514A1 (en) 2004-05-20
US6852724B2 (en) 2005-02-08
US20030100566A1 (en) 2003-05-29
US6369062B1 (en) 2002-04-09
PL348249A1 (en) 2002-05-20
NZ510386A (en) 2003-08-29
PL196263B1 (pl) 2007-12-31
EP1527779A1 (en) 2005-05-04
HK1040060A1 (en) 2002-05-24
PL202207B1 (pl) 2009-06-30
BR9913626A (pt) 2001-12-04
CN1321088A (zh) 2001-11-07
HK1044284A1 (en) 2002-10-18
EP1096937B9 (en) 2007-02-28
EP1096937B1 (en) 2004-12-29
IL175371A0 (en) 2006-09-05
NO20054324L (no) 2001-04-30
MXPA01002598A (es) 2002-04-08
TR200101261T2 (tr) 2002-05-21
EP1109558A2 (en) 2001-06-27
CA2342390C (en) 2006-08-29
PT1096937E (pt) 2005-04-29
DE69901570D1 (de) 2002-06-27
RU2207856C2 (ru) 2003-07-10
SI1109558T1 (en) 2002-10-31
DK1109558T3 (da) 2002-08-26
EP1109558B1 (en) 2002-05-22
AR052921A1 (es) 2007-04-11
CZ2001879A3 (cs) 2001-08-15
CY2008020I2 (el) 2010-07-28
JP3745621B2 (ja) 2006-02-15
US20020090396A1 (en) 2002-07-11
CN1354665A (zh) 2002-06-19
NO2009005I2 (en:Method) 2010-06-28
NO20011192L (no) 2001-04-30
HK1044284B (zh) 2005-07-15
ES2234302T3 (es) 2005-06-16
NO320986B1 (no) 2006-02-20
MXPA01002599A (es) 2005-02-17
WO2000013687A2 (en) 2000-03-16
CY2008020I1 (el) 2010-07-28
CA2343376A1 (en) 2000-03-16
NZ510384A (en) 2002-10-25
AU6036499A (en) 2000-03-27
FR09C0001I2 (en:Method) 2009-12-18
US20050153982A1 (en) 2005-07-14
NO20011192D0 (no) 2001-03-08
PT1109558E (pt) 2002-10-31
US20020004506A1 (en) 2002-01-10
PL347073A1 (en) 2002-03-11
WO2000013686A2 (en) 2000-03-16
AU760435B2 (en) 2003-05-15
CZ2001880A3 (cs) 2001-08-15
WO2000013686A3 (en) 2000-07-06
CN1211086C (zh) 2005-07-20
ATE285774T1 (de) 2005-01-15
TR200101262T2 (tr) 2001-12-21
NO319434B1 (no) 2005-08-15
HUP0103844A2 (hu) 2002-04-29
ES2177346T3 (es) 2002-12-01
JP2006096757A (ja) 2006-04-13
HU224215B1 (hu) 2005-06-28
CN1193757C (zh) 2005-03-23
CZ301341B6 (cs) 2010-01-20
IL141893A (en) 2008-08-07
AR022085A1 (es) 2002-09-04
IL141892A0 (en) 2002-03-10
HUP0104088A2 (hu) 2002-05-29
AU744071B2 (en) 2002-02-14
FR09C0001I1 (en:Method) 2009-02-27
US6562826B1 (en) 2003-05-13
KR20010089874A (ko) 2001-10-12
NO20011191L (no) 2001-04-30
NL300371I1 (nl) 2009-02-02
RU2214233C2 (ru) 2003-10-20
US20030099705A1 (en) 2003-05-29
UA75027C2 (uk) 2006-03-15
DE69922964T2 (de) 2005-12-08
AU2008207707A1 (en) 2008-09-25
SI1096937T1 (en) 2005-04-30
CA2342390A1 (en) 2000-03-16
CA2343376C (en) 2007-01-09
US20060217397A1 (en) 2006-09-28
DE69922964D1 (de) 2005-02-03
UA67793C2 (uk) 2004-07-15
DE122008000065I1 (de) 2009-04-09
NO20011191D0 (no) 2001-03-08
DE69901570T2 (de) 2003-01-09
PL196668B1 (pl) 2008-01-31
LU91504I9 (en:Method) 2019-01-02
US20060147521A1 (en) 2006-07-06
GEP20053420B (en) 2005-01-25
HUP0103844A3 (en) 2002-11-28
HUP0104088A3 (en) 2002-12-28
US6525057B2 (en) 2003-02-25
EP1096937A2 (en) 2001-05-09
AU6142599A (en) 2000-03-27
US6864258B2 (en) 2005-03-08
IL180864A0 (en) 2007-07-04
US20050059667A1 (en) 2005-03-17
KR100475759B1 (ko) 2005-03-10
AR053440A2 (es) 2007-05-09
ATE217794T1 (de) 2002-06-15
CZ301375B6 (cs) 2010-02-03
NO2009005I1 (no) 2009-03-16
DK1096937T3 (da) 2005-05-09
US6617328B2 (en) 2003-09-09
TWI241911B (en) 2005-10-21
US20040029890A1 (en) 2004-02-12
NL300371I2 (nl) 2009-10-01
JP2002524416A (ja) 2002-08-06
US6303607B1 (en) 2001-10-16
BR9913553A (pt) 2001-10-23
WO2000013687A3 (en) 2000-06-29
IL141893A0 (en) 2002-03-10
IL141892A (en) 2006-08-20
AU2008207703A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
LU91504I2 (fr) Ranolazine ou un de ses sels ou solvates
DE69921712D1 (de) Kapazitiver Abstandssensor
NO984772L (no) Tidlig evalueringssystem med boreevne
DE69614974D1 (de) Drehbohrhammer
DE59914142D1 (de) Bohrhammer
LU91540I2 (fr) Robenacoxib-Onsior ou un de ses sels ou prémédicament vétérinairement acceptable
FIU980316U0 (fi) Oviesteen tunnistin
BR9607388A (pt) Ferramenta de furos verticais
PT958198E (pt) Garrafa com parede dupla
FI982738L (fi) Lähettimen linearisointi
DK1089996T3 (da) Paroxetin-methansulfonat-acetonitril-solvat 1:1
DE69805889D1 (de) Schneidtiefenbegrenzer
DK0778391T3 (da) Roterende slag-sneglebor
DE69934776D1 (de) Positionssensor
BR9913430B1 (pt) aparelhagem de profundidade de poÇo.
GB9815826D0 (en) Capacitive position transducer
DE59505872D1 (de) Schlag- oder Drehschlaghammer
DE69941245D1 (de) Kapazitiver sensor
DE59910240D1 (de) Kapazitiver Sensor
PT949019E (pt) Unidade de gofragem
ITMI992509A0 (it) Strumento di livello
DE59911708D1 (de) Betreiben eines wirbelstromsensors
FR2777141B1 (fr) Transpondeur
DE59801609D1 (de) Kombi-Bohrwerkzeug
DE59504945D1 (de) Tiefenmessgerät